Your Health, We Care

Home > Photo Wall > Honor and qualification

Production approval for Pralsetinib

Release date: 2024-07-10 15:05:18     Recommended: 141

08L1007_23 普拉替尼 批文_00.jpg

It is a receptor tyrosine kinase RET (Rearranged during Transfer) inhibitor used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in adult patients with positive RET gene fusion; The treatment of advanced or metastatic RET mutant thyroid medullary carcinoma (MTC) in adults and children aged 12 and above who require systematic treatment, as well as advanced or metastatic RET fusion positive thyroid carcinoma in adults and children aged 12 and above who require systematic treatment and are refractory to radioactive iodine (if radioactive iodine is applicable).

Company News

Research News

Drug news